



Attorney Docket No. 1076.1069

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Applica	ation of:				
Masaya NAMBU					
Application No.: 09	)/892,751	Group Art Unit: 2182			
Filed: June 28, 200	01	Examiner: Unassigned			
For: METHOD F	OR PROVIDING VACCINE SO	FTWARE AND PROGRAM			
	INFORMATION DISCLOS	SURE STATEMENT RECEIVED			
Commissioner for F PO Box 1450 Alexandria, VA 223		NOV 1 3 2003 Technology Center 210			
Sir:					
In accordance with the duty of disclosure provisions of 37 CFR § 1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the subject application.  1. Enclosures accompanying this Information Disclosure Statement are:					
1a. ⊠ 1b. ⊠ 1c. ⊠  1d. ⊠  1e. □  1f. □ 1g. □	application. English language translation (peach non-English language put Explanations of Relevancy of I providing a concise explanation List of Copending Applications	References (ATTACHMENT 1(e), hereto) for not each non-English publication.			
2.	Continued Prosecution Applica Within three months of the dat § 1.491 in an international app Before the mailing of a first Of	a or 2b or 2c or 2d)  g date of a national application other than a ation under § 1.53(d); e of entry of the national stage as set forth in lication.  fice Action on the merits; or fice Action after the filing of a Request for			

Serial No.: 09/892,751

3.		This Information Disclosure Statement is filed under 37 CFR § 1.97(c) after the period specified in paragraph 2 above but before the mailing date of any of a Final Office Action under § 1.113, a Notice of Allowance under § 1.311 or an action that otherwise closes prosecution in the application, AND		
			(Check either Item 3a or 3b; Item 3b to be checked if any reference known for more than 3 months)	
		3a. ☐ 3b. ☐	The §1.97(e) Statement in Item 5 below is applicable; OR The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is:  enclosed.	
			to be charged to Deposit Account No. 19-3935.	
4.		specified 4a.	mation Disclosure Statement is filed under 37 CFR §1.97(d) after the period in paragraph 3 above, but on or before payment of the Issue Fee, AND  The § 1.97(e) Statement in Item 5 below is applicable; AND	
		4b. 🗌	The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is:  enclosed.	
			to be charged to Deposit Account No. 19-3935.	
5. 🗆		Statement under § 1.97(e) (applicable if Item 3a or Item 4a is checked)  (Check either Item 5a or 5b)		
		5a. 🗌	In accordance with 37 CFR § 1.97(e)(1), it is stated that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.	
		5b. 🗌	In accordance with 37 CFR § 1.97(e)(2), it is stated that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known by any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.	
6.		This is a (	continuation/divisional/continuation-in-part application under 37 CFR §	
		. ,	(Check appropriate Items 6a and/or 6b)	
		6a. 🗌	Copies of the publications listed on the attached Form PTO-1449 which were previously cited in prior application Serial No, filed on, and which is relied on for an earlier effective filing date for the subject application under 35 U.S.C. § 120, have been omitted pursuant to 37 CFR	
		6b. 🗌	§ 1.98(d). Copies of the publications listed on the attached Form PTO-1449 which were not previously cited in prior application Serial No, filed on, and which is relied on for an earlier effective filing date for the subject application under 35 U.S.C. § 120, are provided herewith.	

Serial No.: 09/892,751

7.		This is a continuation/divisional application under 37 CFR § 1.53(d) or a Request for Continued Examination under 37 CFR 1.114.			
			(Check either Item 7a or 7b)		
		7a. 🗌 7b. 🗍	The Issue Fee has not been paid. A Petition to Withdraw from issue under 37 CFR § 1.313(c) is filed concurrently herewith or has been granted. A continuation/divisional application under 37 CFR § 1.53(d) or a Request for Continued Examination under 37 CFR 1.114, after payment of the Issue Fee, is proper in accordance with 37 CFR § 1.53(d)(1)(ii) or 37 CFR 1.114(a), respectively.		
8.		This is a	Supplemental Information Disclosure Statement.		
			(Check either Item 8a or 8b)		
		8a. 🗌	This Supplemental Information Disclosure Statement under 37 CFR § 1.97(f) supplements the Information Disclosure Statement filed on A bona fide attempt was made to comply with 37 CFR § 1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental IDS can		
		8b. 🗌	be considered as if properly filed on  This Supplemental Information Disclosure Statement is timely filed within one (1) month of the Notice under 37 CFR § 1.97 and 1.98, mailed		
9.			nce with 37 CFR § 1.98, a concise explanation of what is presently I to be the relevance of each non-English language publication is:  (Check appropriate Items 9a, 9b, 9c and/or 9d)		
		9a. 🗌	satisfied because all non-English language publications were cited on the enclosed "English language version of the search report or action which indicates the degree of relevance found by the foreign office". (See MPEP § 609, Minimum Requirements for an Information Disclosure Statement, Part A(3): Concise Explanation of Relevance, 8th Ed.)		
		9b.	set forth in the application. satisfied because an English language translation (abstract) is attached to non-English language publication.		
		9d. 🗌	enclosed as Attachment 1(e), hereto.		
10.	be th	e, material an search	on is made that the information cited in this Statement is, or is considered to to patentability nor a representation that a search has been made (other report(s) from a counterpart foreign application or a PCT International ort, if submitted herewith). 37 CFR §§ 1.97(g) and (h).		

11. The Commissioner is authorized to credit any overpayment or charge any additional fee required under 37 CFR § 1.17 for this Information Disclosure Statement to Deposit Account No. 19-3935.

Respectfully submitted,

STAAS & HALSEY LLP

Registration No. 28,607

John C. Garvey

1201 New York Ave., N.W., Suite 700

Washington, D.C. 20005 Telephone: (202) 434-1500 Facsimile: (202) 434-1501

©2003 Staas & Halsey LLP

Serial No.: 09/892,751



Sheet 1 of 1 ATTORNEY DOCKET NO. APPLICATION NO. FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE 1076.1069 09/892,751 FIRST NAMED INVENTOR LIST OF REFERENCES CITED BY APPLICANT Masaya NAMBU FILING DATE GROUP ART UNIT (Use several sheets if necessary) June 28, 2001 2182 **U.S. PATENT DOCUMENTS** SUB-\*EXAMINER DOCUMENT **FILING CLASS** INITIAL NO. **CLASS** DATE DATE NAME AA AB RECEIVED AC AD NOV 1 3 2003 ΑE Technology Center 2100 AF **FOREIGN PATENT DOCUMENTS** SUB-**TRANSLATION** DOCUMENT **CLASS** YES NO. **CLASS** DATE COUNTRY AG 05-257675 10/08/93 Japan abstract AH 12/08/98 10-326208 partial Japan ΑI 50-116248 09/11/75 partial Japan AJ AK AL **TRANSLATION** OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.) YES NO AM

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

**EXAMINER**